Explore Our History

Established in 2005 through the merger of Daiichi Pharmaceutical and Sankyo, Daiichi Sankyo has a rich history spanning more than 100 years.


  • 1915

    Founded as Arsemin Shokai by Dr. Katsuzaemon Keimatsu and five others

  • 1915

    Launched Arsemin®, an antisyphilitic agent

  • 1916

    Launched Neo-Arsemin®, another antisyphilitic agent

  • 1918

    Changed company name from Arsemin Shokai to Daiichi Pharmaceutical Co., Ltd.

    Appointed Seinosuke Shibata as first president

  • 1921

    Launched Bosmin®, a vasoconstriction / hemostasis and asthma medicine

  • 1933

    Established plant in Takatsuki, Japan

  • 1937

    Launched Therapol®, the first sulfa drug produced in Japan

  • 1938

    Established plant in Funabori, Japan


  • 1949

    Listed on Tokyo Stock Exchange

  • 1952

    Launched Iscotin®, a medicine for tuberculosis

  • 1965

    Completed construction of head office building in Nihonbashi, Japan

  • 1965

    Launched Transamin®, an antiplasmin medicine

  • 1966

    Launched Patecs®, the first form-fitting pain relief patch

  • 1973

    Launched Karoyan®, a hair restoration agent


  • 1979

    Launched Neuer®, a peptic ulcer agent

  • 1981

    Established plant in Akita, Japan

  • 1983

    Signed out-licensing agreement for Tarivid®, a broad-spectrum antibacterial agent, with Johnson & Johnson of the United States and Hoechst of Germany

  • 1985

    Launched natural-type interferon-β formulation Feron®

  • 1985

    Launched Tarivid® in Japan and then-West Germany

  • 1987

    Launched Omnipark®, a contrast media

  • 1987

    Launched Senlock Pellet® (now Daiichi Sankyo Core Block®), a gastrointestinal agent

  • 1990

    Established Korea Daiichi Pharmaceutical Co., Ltd.

  • 1993

    Launched Cravit®, a broad-spectrum oral antibacterial agent

  • 1994

    Launched Kuromaru Drink®, a digestive tonic

  • 1998

    Established Daiichi Pharmaceutical (Beijing) Co., Ltd. in China

  • 2003

    Launched Cystina C®, an over-the-counter vitamin C product


  • 2005

    Established by joint holding company of Sankyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd.

  • 2006

    Began operations of Daiichi Sankyo Healthcare Co., Ltd.; Daiichi Sankyo, Inc.; and Daiichi Sankyo Europe GmbH

  • 2006

    Launched Urief®, a drug for dysuria (Daiichi Pharmaceutical Co., Ltd.)

  • 2007

    Began operations on April 1, 2007 as Daiichi Sankyo Co., Ltd.

  • 2008

    Acquired U3 Pharma GmbH of Germany and Ranbaxy Laboratories Ltd. of India

  • 2009

    Launched Prasugrel, an antiplatelet agent and global product, in Germany (as Efient®) and the United States (as Effient®)

  • 2010

    Launched Rezaltas®, a high-affinity ARB/long-acting calcium antagonist compound

  • 2010

    Began operations of Daiichi Sankyo Espha Co., Ltd.

  • 2010

    Launched Inavir®, an anti-influenza virus agent

  • 2011

    Acquired Plexxikon Inc. of the United States

  • 2011

    Began operations of Kitasato Daiichi Sankyo Vaccine Co., Ltd.

  • 2011

    Launched Memary® for treatment of Alzheimer's disease

  • 2011

    Launched Lixiana®, an oral FXa inhibitor

  • 2011

    Launched Nexium®, a proton pump inhibitor

  • 2011

    Consolidated Japan head office and head offices of Japan Group companies into three office buildings in the Nihonbashi area of Tokyo, Japan

  • 2011

    Established wholly-owned subsidiary Daiichi Sankyo (China) Holdings Co., Ltd.

  • 2012

    Opened Daiichi Sankyo Kusuri Museum in Tokyo

  • 2012

    Launched RANMARK®, an antibody that targets RANK ligand

  • 2012

    Began operations of Japan Vaccine Co., Ltd., a joint venture with GlaxoSmithKline K.K.

  • 2012

    Launched TENELIA®, a therapeutic agent for type 2 diabetes

  • 2013

    Launched natural tetrahydrobiopterin agent Biopten® Granules 10%

  • 2014

    Launched oral antiplatelet agent Efient in Japan

  • 2014

    Launched CANAGLU® Tablets 100mg for treatment of Type 2 Diabetes Mellitus

  • 2014

    Received approval in Japan for additional AF and VTE indications for LIXIANA® (edoxaban)

  • 2014

    Acquired biopharmaceutical company Ambit Biosciences

  • 2015

    Launched edoxaban, an oral, once-daily anti-coagulant global product, in the United States (as SAVAYSA®) and in Europe (as LIXIANA®)

  • 2015

    Launched Methylene Blue Injection 50mg, a treatment for methemoglobinemia

  • 2015

    Launched MOVANTIK®, a treatment for opioid-induced constipation (OIC), in the United States via co-commercialization agreement with AstraZeneca

  • 2015

    Ranbaxy Laboratories Limited acquired by Sun Pharmaceutical Industries Ltd. via all-stock transition

  • 2015

    Daiichi Sankyo Healthcare acquired mail-order cosmetics and health food business, Im Co., Ltd.

  • 2015

    Launched Squarekids® subcutaneous injection syringe, a tetravalent combination vaccine for the prevention of diphtheria, pertussis, tetanus, and poliomyelitis (polio)